Working… Menu

A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04341389
Recruitment Status : Active, not recruiting
First Posted : April 10, 2020
Last Update Posted : May 18, 2020
CanSino Biologics Inc.
Jiangsu Province Centers for Disease Control and Prevention
Hubei Provincial Center for Disease Control and Prevention
Zhongnan Hospital
Information provided by (Responsible Party):
Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China